About Index Trending news
Analyze
Top 50 Pricing
Sarepta Therapeutics

Sarepta Therapeutics

Work at Sarepta Therapeutics? Add yourself to this profile

Sarepta Therapeutics

Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save

Elsewhere

Alexa global traffic share

Employees

Team size

50+
Locations
HQ
Xconomy

Bio Roundup: Precision Med and Google, Heron, Lilly, Sarepta & More

Xconomy

Sarepta Stock Down as FDA Seeks More Data from Rival Duchenne Drug

Health Earnings
The Motley Fool

Why Envision Healthcare Holdings, Sarepta Therapeutics, and ABM Industries Jumped Today

Stock markets Technology Health
The Motley Fool

Why Sarepta Therapeutics Shares Are Jumping 10% Today

The Motley Fool

Why Sarepta Therapeutics Shares Skyrocketed Today

The Motley Fool

Why Sarepta Therapeutics Shares Skyrocketed 48% in May

The Motley Fool

Why Sarepta Therapeutics, Signet Jewelers, and DeVry Education Group Slumped Today

Stock markets Health
The Motley Fool

Why Sarepta Therapeutics Shares Are Tumbling 19% Today

The Motley Fool

Here's Why Sarepta Therapeutics' Stock Is Surging Higher Today

Xconomy

Sarepta Saga Drags On as FDA Delays Decision on Duchenne Drug

The Motley Fool

Forget Sarepta Therapeutics, This DMD Stock Could Be A Better Buy

The Motley Fool

What's Sarepta Therapeutics Inc.'s Next Move?

The Motley Fool

3 Things You Need to Know Now That Sarepta Therapeutics Has Reported First-Quarter Results

Health Stock markets
The Motley Fool

Why Sarepta Therapeutics Inc. Is Up Big Today

The Motley Fool

Why Sarepta Therapeutics, Allegheny Technologies, and Capital Product Partners Slumped This Morning

Stock markets Earnings
The Motley Fool

Why Sarepta Therapeutics' Stock Is Crashing Today

The Motley Fool

Why Sarepta Therapeutics Inc. Is Bouncing Back Today

The Motley Fool

Why Las Vegas Sands, Sarepta Therapeutics, and United Continental Holdings Slumped Today

Stock markets Earnings
The Motley Fool

Down 41%: Is Sarepta Therapeutics Worth the Risk?

The Motley Fool

Why Sarepta Therapeutics Inc. Soared 44% Higher in March